KB-1185

Enfortumab

52668

Home » Enfortumab

Background of Enfortumab

Nectin-4 is a type I membrane protein. The extracellular region of Nectin-4 dimer consists of three Ig domains, Ig V type and IgC type. Nectin-4 is overexpressed in a variety of tumor cells and can promote the growth and proliferation of tumor cells. Enfortumab vedotin a "first-in-class" drug developed by Astellas and Seagen, is an ADC drug that combines enfortumab targeting Nectin-4 with the microtubule destroyer MMAE via a cleavable dipeptide linker. Enfortumab vedotin binds to Nectin-4 on the surface of tumor cells and enters the tumor cells through endocytotic action. After the dipeptide linker is cleaved by proteolytic enzymes in the cell, the toxin MMAE can be released and targeted to kill the tumor.

Specifications

Catalog Number	KB-1185
Antibody Name	Enfortumab
Isotype	Human-IgG1, kappa
FC Muations	WT
Target	Nectin-4
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Evan Y Yu;Daniel P Petrylak;Peter H O'Donnell;Jae-Lyun Lee;Michiel S van der Heijden;Yohann Loriot;Mark N Stein;Andrea Necchi;Takahiro Kojima;Michael R Harrison;Se Hoon Park;David I Quinn;Elisabeth I Heath;Jonathan E Rosenberg;Joyce Steinberg;Shang-Ying Liang;Janet Trowbridge;Mary Campbell;Bradley McGregor;Arjun V Balar; (2021). Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial . The Lancet Oncology.
Jens Bedke;Moritz Maas; (2021). Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma . European Urology.
Challita-Eid, P. M.; Satpayev, D.; Yang, P.; An, Z.; Morrison, K.; Shostak, Y.; Raitano, A.; Nadell, R.; Liu, W.; Lortie, D. R.; Capo, L.; Verlinsky, A.; Leavitt, M.; Malik, F.; Avina, H.; Guevara, C. I.; Dinh, N.; Karki, S.; Anand, B.; Pereira, D. S.; Joseph, I. B. J.; Donate, F.; Morrison, K.; Stover, D. R. (2016). Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Research, 0008-5472.CAN-15-1313.